Sponsor Preference of CRO Experience in Orphan Drug Trials
Despite the substantial difficulties associated with orphan drug trial recruitment, this segment of the drug development market is booming. By 2020, orphan drug sales are expected to make up 19% of prescription drug sales, excluding generics. In ISR’s Orphan Drug Market Dynamics and Patient Recruitment Best Practices report, ISR provides an overview of the orphan drug development market as well as how to best drive patient recruitment in an area of drug development in which drug developers do not want to be left behind. Read more here.
Source: Industry Standard Research, February 2015
Source: Industry Standard Research, February 2015
Source: Industry Standard Research, February 2015
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.
